Lund, Sweden, 10:00 CET, 17 06 21 BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company's antibiotic eluting product CERAMENT G has been categorized as a breakthrough device for the indication trauma by the US Food and Drug Admini... read more

The trial is now fully recruited with a total of 33 patients enrolled with 30 patients in the full dose ONCOS-102 and durvalumab combination in the colorectal cancer cohort  Oslo, Norway, 17 June 2021 – Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune a... read more

37% CR rate in 30 efficacy-evaluable patients BOSTON, June 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protei... read more

Product candidate FPI-1434, administered at three different dose levels, demonstrated a favorable safety profile with no drug-related serious adverse events or dose-limiting toxicity Imaging shows drug uptake across multiple tumor types Enrollment in multi-dosing cohorts continues Fusion a... read more

Oslo, Norway, 14 June 2021 – Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, has released two video presentations related to the ONCOS-102 mesothelioma 24-month data. The 24-month follow-up data from the rand... read more